Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

By Goodin Douglas S.   Biermann Louis D.   Bohlega Saeed   Boiko Alexey   Chofflon Michel   Gebeily Souheil   Gouider Riadh   Havrdova Eva   Jakab Gabor   Karabudak Rana   Karussis Dimitrios   Miller Ariel   Pakdaman Hossein   Selmaj Krzysztof   Sharief Mohammad    

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2823-2832

Informa Healthcare

Access to resources Recommend Favorite

Sample Size Calculations for Detecting Disease‐Modifying Osteoarthritis Drug Effects on Knee Replacement Incidence in Clinical Trials: Data From the Osteoarthritis Initiative

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 12, 2015-12 ,pp. : 3174-3183

John Wiley & Sons Inc

Access to resources Recommend Favorite

Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

By Brandes David W.   Callender Teri   Lathi Ellen   O’Leary Shirley  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 77-92

Informa Healthcare

Access to resources Recommend Favorite